CASE REPORT
Year : 2015 | Volume
: 56 | Issue : 1 | Page : 74--76
Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm
Abdulaziz Hassan, Livingstone Gayus Dogara, Ahmadu Aliyu Babadoko, Sani Awwalu, Aisha Indo Mamman Department of Haematology, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria
Correspondence Address:
Abdulaziz Hassan Department of Haematology, Ahmadu Bello University Teaching Hospital, PMB 06 Shika, Zaria 810001, Kaduna State Nigeria
The World Health Organisation (WHO) classifies myeloproliferative neoplasm (MPN) into BCR-ABL positive chronic myeloid leukaemia (CML Ph + ) and Ph− MPN. The JAK2 V617F mutation is specific for Ph− MPN and occurs in approximately 50% of primary myelofibrosis. Earlier reports suggest that the occurrence of JAK2 and BCR-ABL mutations are mutually exclusive. However, recent reports have documented the coexistence of BCR-ABL and JAK2 mutation in the same patient mostly following treatment with tyrosine kinase inhibitors (TKIs). We thus report a 60-year-old male with atypical clinical and laboratory features of MPN and the presence of both BCR-ABL and JAK2 Mutations.
How to cite this article:
Hassan A, Dogara LG, Babadoko AA, Awwalu S, Mamman AI. Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm.Niger Med J 2015;56:74-76
|
How to cite this URL:
Hassan A, Dogara LG, Babadoko AA, Awwalu S, Mamman AI. Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm. Niger Med J [serial online] 2015 [cited 2024 Mar 29 ];56:74-76
Available from: https://www.nigeriamedj.com/article.asp?issn=0300-1652;year=2015;volume=56;issue=1;spage=74;epage=76;aulast=Hassan;type=0 |
|
|